Hormonal
SGLT2 inhibitors (specifically empagliflozin and canagliflozin) provide significant cardiovascular benefits, particularly reducing cardiovascular death and heart failure hospitalizations, primarily through hemodynamic mechanisms like intravascular volume reduction, with efficacy potentially modified by the duration of diabetes.
If you have Type 2 Diabetes and existing heart issues, ask your doctor about SGLT2 inhibitors like empagliflozin. They have been proven to significantly reduce the risk of dying from heart causes and hospitalizations for heart failure, likely by reducing fluid volume in the body. This benefit is most pronounced in patients with established cardiovascular disease.
Empagliflozin in the EMPA-REG OUTCOME trial... was the first modern-day AHA to show cardiovascular superiority on three-point MACE... primarily driven by a remarkable 38% relative risk reduction in cardiovascular death... mediation analysis... identified the importance of intravascular volume changes... both the leading mechanistic hypotheses for cardiovascular benefits of SGLT2 inhibitors—the hemodynamic... and the 'thrifty substrate'... accentuate the need for prior heart events as background (i.e., secondary intervention) to obtain the degree of cardiovascular end-point efficacy
Why this rating
Based on large, multi-center CVOTs (EMPA-REG, CANVAS) with clear mortality endpoints, though CANVAS had mixed primary prevention results.
Source
Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms
Harpreet S. Bajaj et al. · Physiology · 2018
DOI 10.1152/physiol.00004.2018
More from this paper
- Intensive glycemic control reduces cardiovascular mortality only in patients with early-stage diabetes (duration <10-15 years), whereas it may increase mortality in patients with long-standing diabetes.Good
- GLP-1 receptor agonists (specifically liraglutide and semaglutide) reduce major adverse cardiovascular events (MACE), with benefits potentially driven by anti-atherogenic or plaque-stabilization properties, particularly in secondary prevention.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →